According to a new report, published by KBV research, The Global Circulating Tumor Cell Market size is expected to reach $29.42 billion by 2031, rising at a market growth of 13.2% CAGR during the forecast period.
The Devices market is expected to witness a CAGR of 13.4% during (2024 - 2031). These include advanced instruments and systems used for detecting, capturing, and analyzing CTCs. Devices such as flow cytometers, microfluidic chips, and immunomagnetic separation tools have gained popularity due to their ability to deliver rapid and accurate results. Integrating automation and artificial intelligence in these devices enhances their performance, making them essential in large-scale cancer screening and diagnostic workflows. The growing adoption of these technologies in clinical laboratories and research institutions underpins the segment’s significant contribution to the market.
The Research and Academic Institutes market dominated the Global Circulating Tumor Cell Market by End User in 2023; thereby, achieving a market value of $12.4 billion by 2031. These institutions play a pivotal role in advancing the understanding of cancer biology and the development of innovative diagnostic and therapeutic solutions. The demand for circulating tumor cell analysis in preclinical studies, drug development, and biomarker research drives this segment. With the growing emphasis on personalized medicine and targeted cancer therapies, research institutes increasingly focus on CTC-related studies, further bolstering the market’s growth.
The CTC Analysis market is expected to witness a CAGR of 13.5% during (2024 - 2031). This segment focuses on downstream processes, including genetic, molecular, and morphological analysis of captured circulating tumor cells. These analyses are crucial for understanding tumor heterogeneity, predicting therapy responses, and monitoring disease progression. With the rising application of genomic and proteomic technologies, this segment continues expanding its utility in clinical and research settings.
The Research, Clinical market dominated the Global Circulating Tumor Cell Market by Application in 2023; thereby, achieving a market value of $18,677.8 million by 2031. This segment’s significant contribution reflects its widespread use in academic and clinical settings for cancer diagnosis, prognosis, and monitoring. Circulating tumor cells (CTCs) are increasingly employed in liquid biopsies, allowing non-invasive insights into tumor biology and metastasis. Their role in identifying genetic mutations and resistance mechanisms supports personalized medicine, further driving the segment’s growth. The segment’s prominence is bolstered by rising investments in oncology research and the adoption of innovative technologies.
The Bone Marrow market is expected to witness a CAGR of 13.6% during (2024 - 2031). Bone marrow specimens are particularly valuable for understanding hematological malignancies and metastasis of solid tumors to the bone. Although less commonly used due to the invasive nature of sample collection, bone marrow analysis provides critical insights into specific cancer types. Advances in diagnostic technologies and targeted therapies are expected to sustain the relevance of this specimen type in specialized cancer research and clinical applications.
Full Report: https://www.kbvresearch.com/circulating-tumor-cell-market/
The Asia Pacific region dominated the Global Circulating Tumor Cell Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $11.12 billion by 2031. The North America region is experiencing a CAGR of 12.5% during (2024 - 2031). Additionally, The Europe region would exhibit a CAGR of 13% during (2024 - 2031).
By Product
By End User
By Specimen
By Technology
By Application